Search the Newsreel

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash

Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …

IMDX Stock Price and Chart — NASDAQ:IMDX

This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) stock, including its current price, market capitalization, key financial stats, and performance over various periods. It also highlights analyst opinions, future earnings expectations, and company details, noting the FDA review for GraftAssureDx and …

Insight Molecular Diagnostics Q2 2026 Earnings Preview

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations

This article provides analyst insights, price targets, and recommendations for Insight Molecular Diagnostics Inc. (7OC0.MU). It lists several instances where analysts from Lake Street and Needham have maintained a "Buy" rating for the company's stock between February 2026 and April 2025. The current stock …

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Earnings Preview: IMDX to Report Financial Results Post-market on August 10

This article announces that IMDX is scheduled to report its financial results after market close on August 10. The report will provide key insights into the company's performance, which investors and analysts will be watching closely.

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …

Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX

Insight Molecular Diagnostics Inc. (IMDX) generated $4.05 million USD last year, primarily from its Diagnostic Tests segment. The United States was the largest contributor to this revenue, accounting for $4.03 million USD. This represents a significant increase from the previous year's figures of $1.88 …

Insight Molecular Diagnostics Inc. Revenue Breakdown – LSE:0KCC

Insight Molecular Diagnostics Inc. (LSE:0KCC) generated significant revenue last year, primarily from its Diagnostic Tests segment. The company's top segment contributed $4.05 million USD, an increase from $1.88 million USD in the prior year. The United States was the largest geographical contributor, accounting for …

Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence

This article provides details on the institutional confidence in Insight Molecular Diagnostics Ord Shs (IMDX), listing key institutional shareholders and their recent changes in shareholdings. It highlights major holders like Broadwood Capital, Inc. and AWM Investment Company, Inc., along with their respective percentage changes …

IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.960|Chg%:-0.030

This page provides a detailed overview of Insight Molecular Diagnostics Ord Shs (IMDX), including its current stock price, key financial figures, and recent performance. The company's stock closed at $4.730, experiencing a 4.64% decrease. Analyst ratings suggest a "Buy" with a significant upside, despite …

Medicare coverage confirmed for iMDx kidney-rejection monitoring test

Insight Molecular Diagnostics (iMDx) announced that a new Lancet study demonstrated its GraftAssure donor-derived cell-free DNA (dd-cfDNA) assay could guide treatment for antibody-mediated rejection in kidney transplant patients, potentially reducing drug use by two-thirds. The company also confirmed Medicare reimbursement coverage from MolDX for …

Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX

This article provides financial information for Insight Molecular Diagnostics Inc. (NASDAQ: IMDX), specifically focusing on its enterprise value to revenue forward. The content, sourced from TradingView, indicates a market closed status with no trades and highlights financial data from ICE Data Services and FactSet. …

Medicare expands coverage for transplant monitoring test, boosting Insight Molecular Diagnostics' GraftAssure adoption.

Medicare has expanded its coverage for donor-derived cell-free DNA (dd-cfDNA) testing, which will increase patient access and testing frequency for kidney and heart transplant recipients. This policy change will benefit Insight Molecular Diagnostics (iMDx) and its GraftAssure transplant monitoring assays, supporting their strategy for …

iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing

Insight Molecular Diagnostics Inc. (iMDx) announced that Medicare has expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care, a move expected to boost the commercial adoption of its GraftAssure™ assays. The new MolDX policy clarifies reimbursement guidelines, increases testing frequency for kidney …

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Insight Molecular Diagnostics Inc. (iMDx) has announced a favorable new Medicare policy that significantly expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. This policy clarifies reimbursement guidelines, increases testing frequencies for transplanted organ patients, and cites iMDx's research, bolstering the commercial …

IMDX Forecast — Price Target — Prediction for 2027

IMDX Q1 2026 Earnings: Narrower-than-expected loss drives stock surge - Trough Earnings Signal

Insight Molecular Diagnostics Inc. SEC 10-Q Report

Insight Molecular Diagnostics (IMDX) Stock Price, News & Analysis